These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 39421736)

  • 1. Advances in targeting tumor microenvironment for immunotherapy.
    Wang L; Zhang L; Zhang Z; Wu P; Zhang Y; Chen X
    Front Immunol; 2024; 15():1472772. PubMed ID: 39421736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of m
    Wu C; Li L; Tang Q; Liao Q; Chen P; Guo C; Zeng Z; Xiong W
    Med Oncol; 2024 May; 41(6):159. PubMed ID: 38761335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development.
    Yasuda T; Wang YA
    Trends Cancer; 2024 Jul; 10(7):627-642. PubMed ID: 38600020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.
    Tuccitto A; Shahaj E; Vergani E; Ferro S; Huber V; Rodolfo M; Castelli C; Rivoltini L; Vallacchi V
    Virchows Arch; 2019 Apr; 474(4):407-420. PubMed ID: 30374798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cancer-related inflammation in the era of immunotherapy.
    Nakamura K; Smyth MJ
    Immunol Cell Biol; 2017 Apr; 95(4):325-332. PubMed ID: 27999432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Landscape of CMV Infection in Cancer Patients: From "Canonical" Diseases Toward Virus-Elicited Oncomodulation.
    El Baba R; Herbein G
    Front Immunol; 2021; 12():730765. PubMed ID: 34566995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
    Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
    Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunosuppressive landscape in tumor microenvironment.
    Liu W; Zhou H; Lai W; Hu C; Xu R; Gu P; Luo M; Zhang R; Li G
    Immunol Res; 2024 Aug; 72(4):566-582. PubMed ID: 38691319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the tumor microenvironment by immunotherapy: part 2.
    Leibovici J; Itzhaki O; Huszar M; Sinai J
    Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL21 Programs Immune Activity in Tumor Microenvironment.
    Sharma S; Kadam P; Dubinett S
    Adv Exp Med Biol; 2020; 1231():67-78. PubMed ID: 32060847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling.
    Chen PY; Wei WF; Wu HZ; Fan LS; Wang W
    Front Immunol; 2021; 12():671595. PubMed ID: 34305902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective.
    Liu J; Bai Y; Li Y; Li X; Luo K
    EBioMedicine; 2024 Sep; 107():105301. PubMed ID: 39178747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current perspectives and trends of CD39-CD73-eAdo/A2aR research in tumor microenvironment: a bibliometric analysis.
    Huang T; Ren X; Tang X; Wang Y; Ji R; Guo Q; Ma Q; Zheng Y; Hu Z; Zhou Y
    Front Immunol; 2024; 15():1427380. PubMed ID: 39188712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments.
    Um-E-Kalsoom ; Wang S; Qu J; Liu L
    Cancer Med; 2024 Oct; 13(19):e70155. PubMed ID: 39387259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
    Pansy K; Uhl B; Krstic J; Szmyra M; Fechter K; Santiso A; Thüminger L; Greinix H; Kargl J; Prochazka K; Feichtinger J; Deutsch AJ
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
    Yang L; Li A; Lei Q; Zhang Y
    J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.